{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=5-Fluorouracil+%285FU%29&page=21", "query": { "intervention": "5-Fluorouracil (5FU)", "page": 21 }, "page_size": 10 }, "pagination": { "page": 21, "page_size": 10, "total_count": 1004, "total_pages": 101, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=5-Fluorouracil+%285FU%29&page=22&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=5-Fluorouracil+%285FU%29&page=20&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T00:17:27.580Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01769508", "title": "Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER2 Positive Esophagogastric Cancer" ], "interventions": [ { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Lapatinib", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2013-02", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2016-06-13", "last_synced_at": "2026-10-15T00:17:27.580Z", "location_count": 9, "location_summary": "Fort Myers, Florida • Orlando, Florida • Pensacola, Florida + 6 more", "locations": [ { "city": "Fort Myers", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Pensacola", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Gainesville", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01769508" }, { "nct_id": "NCT00002470", "title": "Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastrointestinal Carcinoid Tumor", "Lung Cancer" ], "interventions": [ { "name": "recombinant interferon alfa", "type": "BIOLOGICAL" }, { "name": "fluorouracil", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Mid-Atlantic Oncology Program", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1990-09", "completion_date": "2004-01", "has_results": false, "last_update_posted_date": "2013-05-15", "last_synced_at": "2026-10-15T00:17:27.580Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002470" }, { "nct_id": "NCT00580073", "title": "Phase II Trial of Neoadjuvant FOLFOX4 and Cetuximab for Localized Adenocarcinoma of Rectum", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rectal Cancer" ], "interventions": [ { "name": "FOLFOX4", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2007-12", "completion_date": "2009-11", "has_results": true, "last_update_posted_date": "2019-12-13", "last_synced_at": "2026-10-15T00:17:27.580Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00580073" }, { "nct_id": "NCT00002664", "title": "Monoclonal Antibody Therapy and Colony- Stimulating Factor in Treating Patients With Metastatic Colorectal Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "edrecolomab", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "James Ahlgren", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 0, "start_date": "1995-07", "completion_date": "2017-02-22", "has_results": false, "last_update_posted_date": "2017-07-13", "last_synced_at": "2026-10-15T00:17:27.580Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002664" }, { "nct_id": "NCT03563157", "title": "QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Cancer Metastatic", "mCRC" ], "interventions": [ { "name": "Aldoxorubicin Hydrochloride", "type": "BIOLOGICAL" }, { "name": "ALT-803", "type": "BIOLOGICAL" }, { "name": "ETBX-011", "type": "BIOLOGICAL" }, { "name": "ETBX-021", "type": "BIOLOGICAL" }, { "name": "ETBX-051", "type": "BIOLOGICAL" }, { "name": "ETBX-061", "type": "BIOLOGICAL" }, { "name": "GI-4000", "type": "BIOLOGICAL" }, { "name": "GI-6207", "type": "BIOLOGICAL" }, { "name": "GI-6301", "type": "BIOLOGICAL" }, { "name": "haNK", "type": "BIOLOGICAL" }, { "name": "Avelumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Regorafenib", "type": "DRUG" }, { "name": "SBRT", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2018-09-28", "completion_date": "2019-08-21", "has_results": true, "last_update_posted_date": "2024-12-11", "last_synced_at": "2026-10-15T00:17:27.580Z", "location_count": 1, "location_summary": "El Segundo, California", "locations": [ { "city": "El Segundo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03563157" }, { "nct_id": "NCT05189171", "title": "MicroOrganoSphere (MOS) Drug Screen Pilot Trial in Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Colorectal Neoplasms" ], "interventions": [ { "name": "MicroOrganoSphere (MOS) drug screen", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Xilis, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2022-10-25", "completion_date": "2024-03-18", "has_results": false, "last_update_posted_date": "2024-06-28", "last_synced_at": "2026-10-15T00:17:27.580Z", "location_count": 7, "location_summary": "Scottsdale, Arizona • Washington D.C., District of Columbia • Jacksonville, Florida + 4 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Knoxville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05189171" }, { "nct_id": "NCT07821177", "title": "Bladder Preservation or Cystectomy for MIBC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Muscle-Invasive Bladder Carcinoma", "Bladder Cancer", "Urothelial Carcinoma" ], "interventions": [ { "name": "Gemzar", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Adrucil", "type": "DRUG" }, { "name": "Mitomycin", "type": "DRUG" }, { "name": "Radical Cystectomy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2026-09-02", "completion_date": "2029-09", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-10-15T00:17:27.580Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07821177" }, { "nct_id": "NCT00056459", "title": "Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Neoplasms", "Colonic Neoplasms", "Rectal Neoplasms" ], "interventions": [ { "name": "Vatalanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1168, "start_date": "2003-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2020-02-10", "last_synced_at": "2026-10-15T00:17:27.580Z", "location_count": 145, "location_summary": "Birmingham, Alabama • Glendale, Arizona • Tucson, Arizona + 123 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00056459" }, { "nct_id": "NCT07793942", "title": "A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Neoplam", "Advanced Solid Tumors" ], "interventions": [ { "name": "MK-2010", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin or Levoleucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Belzutifan", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Epinephrine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 480, "start_date": "2026-10-27", "completion_date": "2030-07-28", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-15T00:17:27.580Z", "location_count": 4, "location_summary": "Belleville, New Jersey • East Brunswick, New Jersey • Maumee, Ohio + 1 more", "locations": [ { "city": "Belleville", "state": "New Jersey" }, { "city": "East Brunswick", "state": "New Jersey" }, { "city": "Maumee", "state": "Ohio" }, { "city": "Eugene", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT07793942" }, { "nct_id": "NCT00942266", "title": "Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Colon", "Adenocarcinoma of the Rectum", "Recurrent Colon Cancer", "Recurrent Rectal Cancer", "Stage IV Colon Cancer", "Stage IV Rectal Cancer" ], "interventions": [ { "name": "fluorouracil", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "vorinostat", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2009-07", "completion_date": "2011-12", "has_results": true, "last_update_posted_date": "2014-06-23", "last_synced_at": "2026-10-15T00:17:27.580Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00942266" } ] }